Year: 2020
Type: article
Abstract: The micronutrient zinc (Zn2+) is an essential trace element and the second most abundant divalent cation in the body (∼2–4 g of zinc). Zinc has important roles in various biochemical pathways, including as a cofactor of >300 enzymes, maintaining structural integrity, basic cellular functions such as proliferation, DNA and RNA synthesis, controlling the expression of several genes and regulating the immune functions of many cells (T, B and natural killer) [1, 2]. Within zinc finger proteins, zinc is involved in the modulation of nuclear factor-κB (NF-κB), tumour necrosis factor (TNF)-inducible protein 3, tristetraprolin, peroxisome proliferator-activated receptors, nuclear factor erythroid 2-related factor 2 (Nrf2), hepatocyte nuclear factor-4α and Kruppel-associated box domain. Zinc is also essential in the active site of superoxide dismutase (SOD), an important antioxidant enzyme that catalyses the dismutation of superoxide (O2–). Thus, zinc has an important role as an anti-inflammatory and antioxidant agent [3, 4]. According to the recommended dietary allowance, the ideal daily dose for adults is 8 mg/day for women and 11 mg/day for men [5]. The main dietary sources of zinc are seafood (especially oysters), red meat, poultry, wholegrains, beans, nuts, vegetables and dairy products; however, zinc’s bioavailability is lower from plant food sources due to the presence of phytates [5]. Zinc is absorbed by enterocytes via the intestinal zinc transporter and reaches the blood via basolateral membrane zinc transporter 1, where it is bound to albumin in the plasma [6]. Absorbed zinc can be eliminated by different routes such as faeces, urine, semen and sweat, and faecal excretion is sensitive to the amount of zinc in the host. Consequently, enteric excretion of zinc via the biliary–pancreatic axis maintains zinc balance through changes in excretion [6]. Zinc deficiency can be due to nutritional deficiency and is very common in developing countries, mainly in children and the elderly. It may also be associated with diseases such as diabetes, cancer, gastrointestinal disease and chronic kidney disease (CKD) [3]. Changes in zinc homeostasis in CKD patients are already well established in the literature, as shown in Table 1. In contrast, studies have observed high levels of zinc in erythrocytes in CKD patients, indicating an abnormal distribution of zinc between plasma and erythrocytes rather than a zinc plasma deficiency per se [7, 8]. Summary of studies related to zinc status in CKD patients 108 non-dialysis CKD patients 42 healthy individuals 39 patients with arterial hypertension ↓ Zinc plasma levels in CKD (60.6 ± 10.6 μg/dL versus 66.6 ± 10.1 μg/dL) ↑ Urinary zinc excretion according to CKD stage 2853 NHANES participants 204 non-dialysis CKD patients 49 non-dialysis CKD patients 42 healthy individuals 42 HD patients 18 healthy individuals 45 HD patients 20 healthy individuals 50 HD patients 48 healthy individuals 20 HD patients 20 patients 20 healthy individuals PD: 0.68 ± 0.03 μg/dL HD: 0.36 ± 0.04 μg/dL Healthy individuals: 0.76 ± 0.08 μg/dL 94 HD patients 47 healthy individuals 30 HD patients 30 healthy individuals 63 HD patients 20 healthy individuals 29 non-dialysis CKD patients 19 healthy individuals 108 non-dialysis CKD patients 42 healthy individuals 39 patients with arterial hypertension ↓ Zinc plasma levels in CKD (60.6 ± 10.6 μg/dL versus 66.6 ± 10.1 μg/dL) ↑ Urinary zinc excretion according to CKD stage 2853 NHANES participants 204 non-dialysis CKD patients 49 non-dialysis CKD patients 42 healthy individuals 42 HD patients 18 healthy individuals 45 HD patients 20 healthy individuals 50 HD patients 48 healthy individuals 20 HD patients 20 patients 20 healthy individuals PD: 0.68 ± 0.03 μg/dL HD: 0.36 ± 0.04 μg/dL Healthy individuals: 0.76 ± 0.08 μg/dL 94 HD patients 47 healthy individuals 30 HD patients 30 healthy individuals 63 HD patients 20 healthy individuals 29 non-dialysis CKD patients 19 healthy individuals PD, peritoneal dialysis. Summary of studies related to zinc status in CKD patients 108 non-dialysis CKD patients 42 healthy individuals 39 patients with arterial hypertension ↓ Zinc plasma levels in CKD (60.6 ± 10.6 μg/dL versus 66.6 ± 10.1 μg/dL) ↑ Urinary zinc excretion according to CKD stage 2853 NHANES participants 204 non-dialysis CKD patients 49 non-dialysis CKD patients 42 healthy individuals 42 HD patients 18 healthy individuals 45 HD patients 20 healthy individuals 50 HD patients 48 healthy individuals 20 HD patients 20 patients 20 healthy individuals PD: 0.68 ± 0.03 μg/dL HD: 0.36 ± 0.04 μg/dL Healthy individuals: 0.76 ± 0.08 μg/dL 94 HD patients 47 healthy individuals 30 HD patients 30 healthy individuals 63 HD patients 20 healthy individuals 29 non-dialysis CKD patients 19 healthy individuals 108 non-dialysis CKD patients 42 healthy individuals 39 patients with arterial hypertension ↓ Zinc plasma levels in CKD (60.6 ± 10.6 μg/dL versus 66.6 ± 10.1 μg/dL) ↑ Urinary zinc excretion according to CKD stage 2853 NHANES participants 204 non-dialysis CKD patients 49 non-dialysis CKD patients 42 healthy individuals 42 HD patients 18 healthy individuals 45 HD patients 20 healthy individuals 50 HD patients 48 healthy individuals 20 HD patients 20 patients 20 healthy individuals PD: 0.68 ± 0.03 μg/dL HD: 0.36 ± 0.04 μg/dL Healthy individuals: 0.76 ± 0.08 μg/dL 94 HD patients 47 healthy individuals 30 HD patients 30 healthy individuals 63 HD patients 20 healthy individuals 29 non-dialysis CKD patients 19 healthy individuals PD, peritoneal dialysis. Several factors may contribute to and explain zinc deficiency in CKD patients. Studies have demonstrated that a negative zinc balance in CKD patients may be due to decreased intestinal absorption, decreased food intake, uraemic toxicity, bioavailability and increased loss (through the faeces, urine or dialysis) [24, 25]. It is important to remember that many CKD patients are elderly, using multiple medications that can affect taste sensations and increase zinc deficiency [26]. Iron deficiency can also cause low zinc plasma levels, since zinc protoporphyrin is formed instead of protoporphyrin, which incorporates an atom of zinc rather than iron [24, 25]. In fact, studies have shown that zinc supplementation can improve anaemia in these patients [27], while iron supplementation may reduce erythrocyte zinc levels [25]. Oral zinc supplementation appears to be a feasible treatment approach for anaemic patients treated with erythropoiesis-stimulating agent, as oral zinc supplementation reduced the erythropoietin responsiveness index in anaemic haemodialysis (HD) patients [28] and also improved haemoglobin concentrations [29]. Zinc deficiency may be characterized by non-specific symptoms including anorexia, weight loss, growth retardation, alopecia, dermatitis, reduced wound healing, loss of taste, and impaired appetite and immune function [5, 30]. More recently, it has been associated with high blood pressure and hypercholesterolaemia [31], showing a relationship between deficiency of this micronutrient and an increased risk of cardiovascular disease (Figure 1). Causes and consequences of zinc deficiency in CKD patients. Causes and consequences of zinc deficiency in CKD patients. In fact, Lobo et al. [32] discussed a possible association between zinc deficiency and atherosclerosis in CKD patients, due to reduced antioxidant functions performed by zinc. Later, the same group [17] observed that zinc plasma levels in HD patients were negatively associated with TNF-α and electronegative low-density lipoprotein (proatherosclerotic cytotoxic particle) levels, confirming the hypothesis that zinc deficiency in CKD patients may be a further risk factor for the development of atherosclerosis. More recently, Chen et al. [33] showed that among non-institutionalized US adults [2535 adults participating in the National Health and Nutrition Examination Survey (NHANES) 2013–14], high dietary zinc intake was associated with a lower probability of severe abdominal aortic calcification (AAC). Of this population, 18.1% had CKD and presented with lower zinc intake when compared with non-CKD individuals. In CKD patients, higher zinc intake was associated with lower odds of having severe AAC only when adjusted for age, sex and race. However, no association was found between zinc intake and AAC in the fully adjusted model in CKD patients. In addition, they observed that higher zinc serum levels were correlated only with patients using zinc supplements and not with dietary zinc intake. This result is very important because zinc bioavailability can differ depending on the dietary source. The main limitation of this study was the weak emphasis on CKD patients. In addition, the characteristics of CKD patients were not provided and serum zinc levels were evaluated only in a small sample of this population. However, a negative association between zinc intake and AAC has been shown in the general population, which may encourage further studies on zinc intake in CKD patients. Vascular calcification is a common complication in CKD patients, even in non-dialysis patients as reported by Górriz et al. [34], who observed from radiographs of the hand and pelvis of patients with varying CKD stages before dialysis treatment that vascular calcification is a predictor of cardiovascular death. In fact, AAC is a risk factor that has already been established in the literature as predicting cardiovascular events in CKD patients. Calcification of the abdominal aorta was associated independently with cardiovascular events in dialysis and non-dialysis CKD patients, and in the general population [35–38]. The pathophysiology of vascular calcification in CKD patients involves several factors including changes related to oxidative stress, inflammation, imbalance between calcification promoters and inhibitors, changes in extracellular matrix metabolism, and calcium and phosphate metabolism imbalances [39, 40]. In addition, Voelkl et al. [41] observed that zinc serum levels were inversely correlated with a propensity for serum calcification in CKD patients, and they also showed that zinc sulfate supplementation improved vascular calcification in mice with renal failure [41]. Zinc deficiency can inhibit metallothionein production, and decrease competition with iron and copper, promoting an increase in oxidative stress due to increased hydroxyl radical production. Increased oxidative stress induces NF-κB activation and, consequently, increased expression of inflammatory cytokines [42, 43]. In addition, zinc deficiency has also been shown to activate the NLRP3 inflammasome and induce interleukin-1β secretion in an animal model [44]. The benefits of zinc supplementation have been demonstrated for many years and Wang et al. [35] reported, through a systematic review and meta-analysis of 15 randomized controlled trials, the benefits of zinc supplementation on zinc serum levels, protein intake and SOD levels, and in reducing lower levels of C-reactive protein and malonaldehyde. They also showed that the median intervention time was 60 days with a dose of ∼45 mg/day. Zinc sulfate supplementation in mice with subtotal nephrectomy increased the aortic expression of the zinc finger protein TNF-α-induced protein 3 (known as A20), which is a suppressor of the NF-κB transcription factor pathway [41]. In addition, zinc treatment inhibited the activation of the NLRP3 inflammasome by attenuating reactive oxygen species (ROS) production in human peritoneal mesothelial cells [45]. Indeed, few studies have shown a relationship between the induction of Nrf2 expression by zinc supplementation. In endothelial cells, zinc positively regulates glutamate cysteine ligase expression by activating and promoting translocation of the transcription factor Nrf2 to the nucleus [46], and also activates the antioxidant responsive element–Nrf2 pathway in epithelial cells [47]. In human renal tubular cells under diabetic conditions, treatment with zinc significantly increases nuclear expression of Nrf2 [48]. Nrf2 is a transcription factor that, when released from its repressor, the cytosolic protein Keap1, targets the cell’s nucleus by acting on genes encoding Phase II detoxifying enzymes or antioxidant enzymes capable of playing crucial roles in the cell’s defence pathways by improving removal of ROS [49]. Thus, Nrf2 appears to modulate the anti-inflammatory cascade by regulating antioxidant agents and also inhibiting NF-κB [49]. Previous human studies have shown that CKD patients present with downregulation of Nrf2 mRNA expression and upregulation of NF-κB mRNA expression [50], and that zinc supplementation may contribute to increase its expression, as well as to increase SOD synthesis, improve antioxidant defence and reduce cardiovascular risk in CKD patients. The relationship between zinc deficiency, oxidative stress, inflammation and the development of cardiovascular disease has been demonstrated, and researchers suggest that zinc supplementation may reduce the risk and progression of atherosclerosis [17, 51]. Accordingly, in view of all the important functions and biochemical pathways that zinc is involved in, and the fact that CKD patients are zinc deficient, it is important that we do not forget this mineral in our patients’ diet. Also, we need to remember that the food matrix and diet composition are essential for nutritional treatment, and that zinc is a mineral found in our diet. Conselho Nacional de Pesquisa (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). Denise Mafra receives support from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, grant No. 302034/2018-8) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ, grant No. E-26/202.24/2019) The authors declare that there is no conflict of interest regarding the publication of this article. (See related articles by Chen et al. Association between dietary zinc intake and abdominal aortic calcification in US adults. Nephrol Dial Transplant 2020; 35: 1171–1178; Damianaki et al. Renal handling of zinc in chronic kidney disease patients and the role of circulating zinc levels in renal function decline. Nephrol Dial Transplant 2020; 35: 1163–1170)
DOI: 10.1093/ndt/gfaa045
Authors: Ludmila F M F Cardozo, Denise Mafra
Institution: Universidade Federal Fluminense
Language: English
Topic: Trace Elements in Health
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Open Access status: bronze
Awards: G2155603856, G3626612411
OpenAlex ID: W3025250321
